biologic

Nuwiq

Antihemophilic Factor (Recombinant)

Loss of exclusivityJuly 2029projected — 12-year biologic exclusivity estimate
CompanyOctapharma Pharmazeutika Produktionsges.m.b.H.

Drug detail

Brand nameNuwiq
Active ingredientAntihemophilic Factor (Recombinant)
Strength4000IU
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalJuly 2017
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Not found